Table 1.

Comparison of biological activities of anti-DEN-2 virus MAbs

Epitope (MAb)E-glycoprotein domain90% PRNTaFusion BlockingELISA resultbMaximum % blockingcLog10 MAb dilution exhibiting blockingf
BoundCaptured
A1 (6B6C-1)II±+5.2≥5.318 (11)1
A1 (4G2)II+NDd 5.3≥5.332 (9)1–2
A2 (4E5)II++4.22.612 (12)5
A3 (1A5D-1)II5.33.5NAe
A5 (1B7)II++5.3≥5.323 (6)1–3
A/C (10A1D-2)I/II4.42.9NA 
C1 (1B4C-2)I6.2≥5.346 (15)2, 6
C2 (4A5C-8)I3.22.0NDND 
C3 (2B3A-1)I5.32.0NDND 
C4 (9A4D-1)I4.42.9NDND 
B1 (3H5)III+ND 5.3≥5.336 (9)3–5
B2 (9A3D-8)III+5.8≥5.342 (6)2–3
B3 (10A4D-2)III+5.3≥5.344 (7)2–5
B4 (1A1D-2)III+5.3≥5.349 (9)2–5
B4 (9D12)III+NDND41 (7)1–5
DEN-2 virus HIAFNA++++34 (18)1–5
DEN-1 virus (1F1)NA≤1.0≤1.010 (12)None
  • a Plaque reduction neutralizing activity (PRNT) at a 1:100 dilution of ascitic fluid (19).

  • b Values are reciprocal end-point titers (log10) determined by plate-bound (indirect) or antibody-captured virus (four-layer) ELISA (19).

  • c Values are average maximum percent blocking based on six replicates (values in parentheses are 95% CIs). —, antibodies enhanced virus binding.

  • d ND, not done.

  • e NA, not applicable.

  • f We considered a MAb to significantly block adsorption only if the percent blocking minus the 95% CI was greater than zero.